[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349853-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349853-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","syndna-vaccine-against-tcr-chains-and-neoantigens-for-t-cell-lymphoma-therapy","synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy","","T cell lymphomas account for about 10% of non-Hodgkin lymphomas and have poor prognosis, with early relapse associated with a 5-year overall survival of 11%. The clonality of T cell cancers makes the T cell receptor (TCR) a compelling immunotherapy target. A synDNA vaccine targeting the TCRα, β, and γ chains (TCRfullvax) induced robust T cell responses and broke tolerance without broadly depleting T cells. In a minimal residual disease model, vaccination delayed tumor progression and tumors showed TCR downregulation consistent with immune escape. A second vaccine (EL4neovax) targeting 15 identified neoantigens elicited strong responses to 5/15 and controlled EL4 tumors. Combined administration improved tumor control compared with either vaccine alone, supporting dual TCR and neoantigen targeting to mitigate TCR loss and guide further optimization.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/syndna-vaccine-against-tcr-chains-and-neoantigens-for-t-cell-lymphoma-therapy/349853/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/syndna-vaccine-against-tcr-chains-and-neoantigens-for-t-cell-lymphoma-therapy/349853.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the synDNA vaccine approach address in T cell lymphomas?","Question",{"text":63,"@type":64},"The work targets poor outcomes in T cell lymphomas by improving immunotherapy strategies. It focuses on breaking immune tolerance and enhancing T cell responses against specific antigen targets.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the TCR-targeting vaccine (TCRfullvax) designed and evaluated?",{"text":68,"@type":64},"TCRfullvax was developed for the EL4 murine T cell lymphoma model to target the TCRα, β, and γ chains. Immunogenicity studies assessed T cell responses and identified immunodominant epitopes for each chain.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the rationale and outcome of combining TCRfullvax with the neoantigen vaccine (EL4neovax)?",{"text":72,"@type":64},"The combination aims to improve tumor control while partially mitigating TCR loss observed after TCR-targeted vaccination. Co-administration produced superior tumor control compared with either vaccine design alone and supported dual targeting of T cell lymphomas.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349853,1790193841,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Cancer Immunology, Immunotherapy (2026) 75:80  \n[https://doi.org/10.1007/s00262-026-04302-5](https://doi.org/10.1007/s00262-026-04302-5)  \nsynDNA vaccine against TCR chains and neoantigens forT cell lymphoma therapy  \nPratik S. Bhojnagarwala1 · Devivasha Bordoloi1,2 · Joshua Jose1 · Alfredo Perales‑Puchalt3 · Jian Yan3 · NiranjanY. Sardesai3 · David B. Weiner1  \nReceived: 10 November 2025 / Accepted: 9 January 2026 © The Author(s) 2026  \nAbstract  \nT cell lymphomas constitute approximately 10% of all non-Hodgkin lymphomas and are associated with poor prognosis. Patients experiencing early relapse post-treatment exhibit a 5-year overall survival rate of 11%, underscoring the need for improved therapeutic strategies. The clonality of T cell cancers makes the T cell receptor (TCR) an appealing target for immunotherapy. Here, we developed and evaluated a synDNA vaccine against the TCR⍺ , β, and γ chains (TCRfullvax) of the EL4 murine T cell lymphoma model. Immunogenicity studies revealed induction of robust T cell responses against all three TCR chains, with identification of immunodominant epitopes for each chain. Notably, we observed no significant differences in the number of live T cells between TCRfullvax-vaccinated group and control groups, indicating the vaccine's ability to selectively break tolerance against vaccinated TCR without broadly depleting T cells. In a minimal residual disease model, TCRfullvax delayed EL4 tumor progression. Tumors from TCRfullvax-treated mice revealed downregulation ofTCR expression, suggesting a potential immune escape mechanism. Neoantigens, derived from somatic mutations within tumor genome, present another promising target for anticancer vaccine development, accordingly we developed a second vaccine targeting 15 neoantigens identified through sequencing of EL4 cells (EL4neovax) . EL4neovax elicited strong immune responses against 5/15 encoded neoantigens and controlled EL4 tumors. Co-administration of TCRfullvax and EL4neovax demonstrated superior tumor control compared to either vaccine design alone, further supporting that neoantigen targeting can partially mitigate TCR loss. These findings highlight the potential of combining TCR-targeted and neoantigen-based immunotherapies for the treatment of T cell lymphomas. Further investigation of this dual-vaccine approach is warranted to optimize the therapeutic efficacy for this difficult disease.  \nKeywords Neoantigens · DNA medicine · Immunotherapy · T cell lymphoma · TCR targeting  \nIntroduction  \nT cell lymphomas (TCLs) represent about 10% of all non-Hodgkin’s Lymphomas (NHL) and can be divided into several categories based on maturation stage of the T cell at time of tumorigenesis [1, 2] . TCLs are a relatively rare tumor with fewer than 8000 new diagnoses in the US  \n* David B. Weiner [dweiner@wistar.org](dweiner@wistar.org)  \n1 The Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA  \n2 Present Address: The Indian Institute of Science Education and Research (IISER), Bhopal, Madhya Pradesh, India  \n3 Geneos Therapeutics, Philadelphia, PA, USA  \nannually [3] . TCLs are heterogenous and can be subdivided into more than 30 different subcategories according to the World Health Organization [4]. The diversity and heterogeneity of TCLs account for significant differences in patient prognosis and results in very few therapeutic options which are specific for TCLs [3] . Peripheral T cell lymphomas (PTCLs) comprise of about 26% of all TCLs and are the most common form with few therapeutic options, especially in the relapsed/refractory setting [2] . For cutaneous T cell lymphoma (CTCL), which is considered a less aggressive tumor, the median survival for patients diagnosed with stage III/IV disease is 5 years [5] . On the other hand, the median survival for PTCL patients is 5 months for refractory patients and 11 months for relapsed patients [6] . These statistics underscore the need for new approaches to better impact pat","cbCaikKME5rXo1pq","https://ap.wps.com/l/cbCaikKME5rXo1pq","pdf",1282775,14,"English","# Abstract\n# Introduction","[{\"question\":\"What problem does the synDNA vaccine approach address in T cell lymphomas?\",\"answer\":\"The work targets poor outcomes in T cell lymphomas by improving immunotherapy strategies. It focuses on breaking immune tolerance and enhancing T cell responses against specific antigen targets.\"},{\"question\":\"How was the TCR-targeting vaccine (TCRfullvax) designed and evaluated?\",\"answer\":\"TCRfullvax was developed for the EL4 murine T cell lymphoma model to target the TCRα, β, and γ chains. Immunogenicity studies assessed T cell responses and identified immunodominant epitopes for each chain.\"},{\"question\":\"What is the rationale and outcome of combining TCRfullvax with the neoantigen vaccine (EL4neovax)?\",\"answer\":\"The combination aims to improve tumor control while partially mitigating TCR loss observed after TCR-targeted vaccination. Co-administration produced superior tumor control compared with either vaccine design alone and supported dual targeting of T cell lymphomas.\"}]","synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy | PDF",1790085989,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fbb191902dc2d051937c64a09a1ba4d0.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1fa0bd589af05f473276caeb8e02bb40.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1180a05dff0ed3a61c38b4b9d722c0b6.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3315f98d102de0815d4c1934b25cfb18.webp",980,1301]